The supply price of Bharat Biotech's COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.
The Centre's supplying price is pushing the pricing structure for the private sector upward.
"Fundamental business reasons ranging from low procurement volumes, high distribution costs and retail margins among few others contribute to higher pricing of Covaxin," Bharat Biotech said justifying the higher price when compared to other COVID-19 vaccines available for the private sector in India.
"The supply price of Covaxin to the government of India at Rs 150 / dose, is a non-competitive price and clearly not sustainable in the long run. Hence a higher price in private markets is required to offset part of the costs," Bharat Biotech said in a statement.
Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin, it added.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Unveils Next-Gen Oral Cholera Vaccine To Address Global Health Gaps Bharat Biotech Launches Oral Cholera Vaccine After Successful Phase 3 Trial Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Gas Leak, Then Blast: CCTV Shows Moments After Jaipur Crash That Killed 11 11 Dead, Many Critical In Jaipur Fire As 2 Trucks Collide Outside Petrol Pump Atul Subhash's Mother Goes To Top Court For 4-Year-Old Grandson's Custody Mohan Bhagwat's Statement Should Be Welcomed by All Scientists May Have Finally Figured Why Stonehenge Was Built Number Of Gas Leak Incidents More Than Doubled In Last Decade: Centre Track Latest News Live on NDTV.com and get news updates from India and around the world.